Sort
51,593 grants matching “hepatitis”
Women's Risk Networks: Resources, Infection and Change
$703,283Columbia University Health Sciences · R01 · FY2002 · DA
STD and AIDS Research Training Grant
$703,251Anna Wald · University Of Washington · T32 · FY2022 · AI
Control of vesicular trafficking in the hepatocyte
$703,234Allan W Wolkoff · Albert Einstein College Of Medicine · R01 · FY2019 · DK
ECONOMIC COST OF DRUG USE AND ABUSE
$703,214Rosalie Pacula · Rand Corporation · R01 · FY2007 · DA
STD and AIDS Research Training Grant
$703,169Sheila A. Lukehart · University Of Washington · T32 · FY2017 · AI
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)
$703,062Steven Foung · Stanford University · U19 · FY2021 · AI
Pharmacogenetics of the Statin Response
$702,973Tufts University Boston · R01 · FY2003 · HL
Technology Development Project
$702,943William Nicholas Haining · Massachusetts General Hospital · U19 · FY2012 · AI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control
$702,924Raymond T Chung · Massachusetts General Hospital · R01 · FY2012 · DA
Development and Validation of a Novel and HIV-Relevant Prediction Model for Fracture
$702,912Evelyn Hsieh · Yale University · R01 · FY2022 · AR
Regulation of Hepatic Gluconeogenesis by the CREB:TORC2 Pathway
$702,884Marc R Montminy · Salk Institute For Biological Studies · R37 · FY2010 · DK
Development of Novel Therapies or Methamphetamine Abuse
$702,880Linda P Dwoskin · University Of Kentucky · U01 · FY2016 · DA
Technology Core - The Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern University (C-THAN)
$702,878Sally M McFall · Northwestern University · U54 · FY2024 · EB
Long-Acting, Short-Residing Nanochelators for Iron Overload Therapy
$702,873Hak Soo Choi · Massachusetts General Hospital · R01 · FY2024 · HL
Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention
$702,843Shirish S Barve · University Of Louisville · R01 · FY2022 · AA
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
$702,819Maria Mori Brooks · University Of Pittsburgh At Pittsburgh · U24 · FY2025 · HL
HBV Capsid Effectors
$702,799Raymond F. Schinazi · Emory University · R01 · FY2023 · AI
HBV Capsid Effectors
$702,799Raymond F. Schinazi · Emory University · R01 · FY2025 · AI
Technical Validation of MRI Biomarkers of Liver Fat
$702,743Claude B Sirlin · University Of California, San Diego · R01 · FY2012 · DK
Predict, Detect, Diagnose: Confronting Outbreaks of HIV and Other Infectious Diseases Among People Who Use Drugs
$702,735Gregg Steven Gonsalves · Yale University · R01 · FY2025 · DA
Novel Pathways for Kidney Stone Formation
$702,533Eric N Taylor · Brigham And Women'S Hospital · R01 · FY2021 · DK
Natural model for evaluating within- and cross-species virus transmission
$702,509Ryan Langlois · University Of Minnesota · R01 · FY2025 · AI
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
$702,493Monika Sarkar · University Of California, San Francisco · R01 · FY2023 · DK
Evaluating a Microfinance Intervention for High Risk Women in Kazakhstan
$702,446Nabila El-Bassel · Columbia Univ New York Morningside · R01 · FY2015 · DA
Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool
$702,387Haesuk Park · University Of Florida · R01 · FY2023 · DA